Citiliv-P 800 Tablet
By Citiliv-P
Rx
10 Tablet in a Strip

Composition
Citicoline(500mg) + Piracetam(800mg)

Manufacturer - Heveren Healthcare Pvt Ltd
Plot No-39, Niranjan Vihar 1st, Sirsi Road, Near Bindayaka Industrial Area Phase-1, P.O Bindayaka, District- Jaipur(Rajasthan). Pincode-302012 Plot No-39, Niranjan Vihar 1st, Sirsi Road, Near Bindayaka Industrial Area Phase-1, P.O Bindayaka, District- Jaipur(Rajasthan). Pincode-302012

Expires on or after
August, 2025

liver
Citiliv-P 800 Tablet is considered safe for patients with liver disease. The available data indicates that adjusting the dosage of Citiliv-P 800 Tablet may not be necessary for individuals with liver conditions. It is recommended to consult your doctor if you have liver impairment or any related concerns before using this medication.

kidney
Citiliv-P 800 Tablet should be used cautiously in patients with kidney disease. Dose adjustment may be necessary, especially for those with kidney impairment. It is not recommended for patients with severe kidney disease. Please consult your doctor for guidance.

alcohol
Caution Avoid alcohol with Citiliv-P 800 Tablet Tablet as it may cause increased drowsiness. Consult your doctor.

driving
Caution should be taken when driving after taking Citiliv-P 800 Tablet, as it may cause drowsiness, nervousness, and shakiness. These side effects could impair your focus and reaction time while driving. Avoid driving or operating machinery if affected.

pregnancy
It is better to consult your doctor before using Citiliv-P 800 Tablet.

breastfeeding
It is better to consult your doctor before using Citiliv-P 800 Tablet during breastfeeding, as there is no specific safety information available. Your doctor will determine if it is safe for breastfeeding mothers to take this medication.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | NEURO CNS |
Action Class | - |
₹610
Inclusive of all taxes
Content verified by

Dr. Gowri Kulkarni
MBBS - General Medicine, DNB - Psychiatry, MRCGP [INT] Family Medicine, BSIC (BACP)
Last update on 18-Nov-2024